American Heart Association Scientific Sessions

Importance of Targeting LDL-C

Trial Designs Compared Statins

Are Statins Enough?

Residual Risk Poorly Managed

PCSK9 Inhibitors

How Low is Too Low?

Please join us as we move on to the next interview.

PCSK9 Inhibitors Clinical Trials

Practicalities of PCSK9 Inhibitors

Few Clinical Barriers

PCSK9 Inhibitors Their Place in the Armamentarium

2013 ACC/AHA Guidelines

Role of PCSK9 Inhibitor in Future Recommendation

Future Drug Therapy

Closing Thoughts

Abbreviations

References

References (cont)

References (cont)